Prostate Cancer Diagnostics
Advertisement
PSMA PET/CT can act as a better alternative to MRI, but research on second-generation PSMA PET radioligands is limited.
The FDA has accepted an NDA for TLX007-CDx, a cold kit for the preparation of PSMA-PET imaging for prostate cancer.
About 1 in 12 patients who undergo non-targeted prostate biopsy with a result of GGG 1 PC may have more aggressive cancer.
Patients were sorted into groups based on modifiable lifestyle behaviors and genetic risk.
Researchers trained and externally validated an AI system to detect Gleason grade group 2 or higher cancers.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
New research provides evidence of 18F-rhPSMA-7 leading to more favorable disease outcomes for patients with BCR after RP.
COBRA trial shows 64Cu-SAR-bisPSMA improves detection of recurrent prostate cancer with high specificity.
Dr. Zhang expands on treatment outcomes for patients with prostate cancer after imaging with Ga68-PSMA-PET.
Researchers found no differences between the proportion of distant metastases in the salvage PBRT and WPRT groups.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Dr. Nyame shared highlights from his presentation on PC screening in high-risk groups as part of an AUA plenary session.
The utility of cADT in patients with prostate cancer with clinical relapse at PSMA PET is unknown.
Dr. Vandekerkhove explains her research on genomic testing in prostate cancer.
The benefits of PSA screening alone are offset by excess negative biopsies and the over-detection of low-grade cancers.
Dr. Iagaru discusses the safety findings and clinical implications of his research.
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
Prostate-specific antigen density was the only clinical variable significantly associated with csPCa other than PI-RADS 5.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.